Real-World Insights Into First-Line Use of Topical Roflumilast Cream for Psoriasis
Main Article Content
Keywords
roflumilast cream 0.3%, Psoriasis, real-world evidence, treatment patterns
Abstract
Roflumilast cream 0.3% was approved for the treatment of plaque psoriasis in patients aged ≥12 years in July 2022 and for patients aged 6-11 years in October 2023. This real-world analysis was conducted to understand treatment patterns among patients who filled a roflumilast cream prescription for plaque psoriasis.
A retrospective administrative claims analysis of the IQVIA PharMetrics Plus database (2021–2024) was conducted to evaluate treatment patterns among patients initiating roflumilast cream 0.3% for plaque psoriasis. The index date was defined as the first claim for roflumilast cream 0.3%, with 6-month pre- and post-index periods to assess prior, subsequent, and/or concomitant therapies.
There were 1213 patients with a claim for roflumilast cream 0.3%, most (69%) treated with roflumilast monotherapy; 2 (<1%) initiated roflumilast cream in combination with a biologic agent. There were 303 patients (25%) with no psoriasis treatment in the 6-month pre-index period. Of these treatment-naive patients, 259 (83%) initiated topical roflumilast monotherapy. Among 44 patients who initiated roflumilast cream in a combination regimen, 39 (89.6%) used another topical agent, 2 (4.5%) an oral phosphodiesterase 4 inhibitor (PDE4), and 2 (4.5%) a biologic agent. Within the 6-month post-index period, 14/303 (4.6%) treatment-naive patients initiated a biologic agent.
In this real-world analysis, a substantial portion of patients used roflumilast cream 0.3% as first-line therapy for plaque psoriasis, the majority as monotherapy. Most treatment-naive patients who initiated topical roflumilast as monotherapy did not initiate a subsequent treatment during the 6-month follow-up period, and only a small portion escalated to biologic therapy or an oral PDE4 inhibitor. Among patients who initiated roflumilast cream, <1% (2/303) did so in combination with a biologic agent. These findings suggest that roflumilast cream 0.3% is frequently utilized as a monotherapy and an initial treatment option, suggesting topical roflumilast may help delay or reduce the need for oral and biologic therapy in routine clinical practice.
Sponsored by Arcutis Biotherapeutics, Inc.
References
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.